EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra

Melanie J Plastini iD, Carla Abdelnour, Christina B Young, Edward N Wilson iD, Marian Shahid-Besanti iD, Jennifer Lamoureux, Katrin I Andreasson, Geoffrey A Kerchner, Thomas J Montine, Victor W Henderson, Kathleen L Poston iD

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Melanie J Plastini und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Lewy Body Disease, Biomarkers, alpha-Synuclein. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Alzheimer's Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

More than half of neurodegenerative disease patients have multiple pathologies at autopsy; however, most receive one diagnosis during life. We used the α‐synuclein seed amplification assay (αSyn‐SAA) and CSF biomarkers for amyloidosis and Alzheimer's disease (AD) neuropathological change (ADNC) to determine the frequency of co‐pathologies in participants clinically diagnosed with Lewy body (LB) disease or AD.

Methods

Using receiver operating characteristic analyses on retrospective CSF samples from 150 participants determined αSyn‐SAA accuracy, sensitivity, and specificity for identifying clinically defined LB disease and predicting future change in clinical diagnosis. CSF biomarkers helped determine the frequency of concomitant Lewy body pathology, ADNC, and/or amyloidosis in participants with LB disease and AD, across clinical spectra.

Results

Following a decade‐long follow‐up, the clinically or autopsy‐defined diagnosis changed for nine participants. αSyn‐SAA demonstrated improved accuracy (91.3%), sensitivity (89.3%), and specificity (93.3%) for identifying LB disease compared to all non‐LB disease, highlighting the limitations of clinical diagnosis alone. When examining biomarkers of co‐pathology, amyloidosis was present in 18%, 48%, and 71% ( χ 2 (2) = 13.56, p = 0.001) and AD biomarkers were present in 0%, 8.7%, and 42.9% ( χ 2 (2) = 18.44, p < 0.001) of LB disease participants with different stages of cognitive impairment respectively. Co‐occurring biomarkers for αSyn‐SAA and amyloidosis were present in 12% and 14% of AD compared to 43% and 57% LB disease participants with different stages of cognitive impairment ( χ 2 (3) = 13.87, p = 0.003).

Interpretation

Our study shows that using a combination of αSyn‐SAA and AD biomarkers can identify people with αSyn, ADNC, and co‐pathology better and earlier than traditional clinical diagnostic criteria alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseLewy Body DiseaseBiomarkersalpha-SynucleinHumansAgedMaleFemaleAged, 80 and overRetrospective StudiesMiddle AgedAmyloidosisSensitivity and Specificity

Substanzen

Biomarkersalpha-Synuclein

Autor:innen und Institutionen

  • Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA.
  • Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, USA.
  • Amprion Clinical Laboratory, San Diego, California, USA.
  • Chan Zuckerberg Biohub, San Francisco, California, 94158, USA.
  • Pharma Research and Early Development, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.

ORCID-Profile: Melanie J Plastini, Edward N Wilson, Marian Shahid-Besanti, Kathleen L Poston

Förderung

  • NINDS NIH HHS
  • NIA NIH HHS
  • Alzheimer's Association
  • National Institute on Aging
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Plastini, M. J., Abdelnour, C., Young, C. B., Wilson, E. N., Shahid-Besanti, M., Lamoureux, J., Andreasson, K. I., Kerchner, G. A., Montine, T. J., Henderson, V. W., & Poston, K. L. (2024). Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52034

Vancouver

Plastini MJ, Abdelnour C, Young CB, Wilson EN, Shahid-Besanti M, Lamoureux J, et al. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52034

BibTeX
@article{Plastini2024,
  author = {Plastini, Melanie J and Abdelnour, Carla and Young, Christina B and Wilson, Edward N and Shahid-Besanti, Marian and Lamoureux, Jennifer and Andreasson, Katrin I and Kerchner, Geoffrey A and Montine, Thomas J and Henderson, Victor W and Poston, Kathleen L},
  title = {Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52034}
}
Kostenlos starten →